Micronutrient Fortification to Improve Growth and Health of Maternally HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial
Identifieur interne : 002B37 ( Pmc/Corpus ); précédent : 002B36; suivant : 002B38Micronutrient Fortification to Improve Growth and Health of Maternally HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial
Auteurs :Source :
- PLoS ONE [ 1932-6203 ] ; 2010.
Abstract
The period of complementary feeding, starting around 6 months of age, is a time of high risk for growth faltering and morbidity. Low micronutrient density of locally available foods is a common problem in low income countries. Children of HIV-infected women are especially vulnerable. Although antiretroviral prophylaxis can reduce breast milk HIV transmission in early infancy, there are no clear feeding guidelines for after 6 months. There is a need for acceptable, feasible, affordable, sustainable and safe (AFASS by WHO terminology) foods for both HIV-exposed and unexposed children after 6 months of age.
We conducted in Lusaka, Zambia, a randomised double-blind trial of two locally made infant foods: porridges made of flour composed of maize, beans, bambaranuts and groundnuts. One flour contained a basal and the other a rich level of micronutrient fortification. Infants (n = 743) aged 6 months were randomised to receive either regime for 12 months. The primary outcome was stunting (length-for-age Z<−2) at age 18 months. No significant differences were seen between trial arms overall in proportion stunted at 18 months (adjusted odds ratio 0.87; 95% CI 0.50, 1.53; P = 0.63), mean length-for-age Z score, or rate of hospital referral or death. Among children of HIV-infected mothers who breastfed <6 months (53% of HIV-infected mothers), the richly-fortified porridge increased length-for-age and reduced stunting (adjusted odds ratio 0.17; 95% CI 0.04, 0.84; P = 0.03). Rich fortification improved iron status at 18 months as measured by hemoglobin, ferritin and serum transferrin receptors.
In the whole study population, the rich micronutrient fortification did not reduce stunting or hospital referral but did improve iron status and reduce anemia. Importantly, in the infants of HIV-infected mothers who stopped breastfeeding before 6 months, the rich fortification improved linear growth. Provision of such fortified foods may benefit health of these high risk infants.
Controlled-Trials.com
Url:
DOI: 10.1371/journal.pone.0011165
PubMed: 20567511
PubMed Central: 2887362
Links to Exploration step
PMC:2887362Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Micronutrient Fortification to Improve Growth and Health of Maternally HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial</title></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20567511</idno><idno type="pmc">2887362</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887362</idno><idno type="RBID">PMC:2887362</idno><idno type="doi">10.1371/journal.pone.0011165</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">002B37</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002B37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Micronutrient Fortification to Improve Growth and Health of Maternally HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial</title></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The period of complementary feeding, starting around 6 months of age, is a time of high risk for growth faltering and morbidity. Low micronutrient density of locally available foods is a common problem in low income countries. Children of HIV-infected women are especially vulnerable. Although antiretroviral prophylaxis can reduce breast milk HIV transmission in early infancy, there are no clear feeding guidelines for after 6 months. There is a need for acceptable, feasible, affordable, sustainable and safe (AFASS by WHO terminology) foods for both HIV-exposed and unexposed children after 6 months of age.</p></sec><sec><title>Methods and Findings</title><p>We conducted in Lusaka, Zambia, a randomised double-blind trial of two locally made infant foods: porridges made of flour composed of maize, beans, bambaranuts and groundnuts. One flour contained a basal and the other a rich level of micronutrient fortification. Infants (n = 743) aged 6 months were randomised to receive either regime for 12 months. The primary outcome was stunting (length-for-age Z<−2) at age 18 months. No significant differences were seen between trial arms overall in proportion stunted at 18 months (adjusted odds ratio 0.87; 95% CI 0.50, 1.53; P = 0.63), mean length-for-age Z score, or rate of hospital referral or death. Among children of HIV-infected mothers who breastfed <6 months (53% of HIV-infected mothers), the richly-fortified porridge increased length-for-age and reduced stunting (adjusted odds ratio 0.17; 95% CI 0.04, 0.84; P = 0.03). Rich fortification improved iron status at 18 months as measured by hemoglobin, ferritin and serum transferrin receptors.</p></sec><sec><title>Conclusions</title><p>In the whole study population, the rich micronutrient fortification did not reduce stunting or hospital referral but did improve iron status and reduce anemia. Importantly, in the infants of HIV-infected mothers who stopped breastfeeding before 6 months, the rich fortification improved linear growth. Provision of such fortified foods may benefit health of these high risk infants.</p></sec><sec><title>Trial registration</title><p>Controlled-Trials.com <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/mrct/trial/835053/ISRCTN37460449">ISRCTN37460449</ext-link></p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Shrimpton, R" uniqKey="Shrimpton R">R Shrimpton</name></author><author><name sortKey="Victora, C" uniqKey="Victora C">C Victora</name></author><author><name sortKey="De Onis, M" uniqKey="De Onis M">M de Onis</name></author><author><name sortKey="Lima, R" uniqKey="Lima R">R Lima</name></author><author><name sortKey="Blossner, M" uniqKey="Blossner M">M Blössner</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Filteau, S" uniqKey="Filteau S">S Filteau</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Mofenson, L" uniqKey="Mofenson L">L Mofenson</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lunney, K" uniqKey="Lunney K">K Lunney</name></author><author><name sortKey="Jenkins, A" uniqKey="Jenkins A">A Jenkins</name></author><author><name sortKey="Tavengwa, N" uniqKey="Tavengwa N">N Tavengwa</name></author><author><name sortKey="Majo, F" uniqKey="Majo F">F Majo</name></author><author><name sortKey="Chidhanguro, D" uniqKey="Chidhanguro D">D Chidhanguro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dewey, K" uniqKey="Dewey K">K Dewey</name></author><author><name sortKey="Brown, K" uniqKey="Brown K">K Brown</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Gitau, R" uniqKey="Gitau R">R Gitau</name></author><author><name sortKey="Makasa, M" uniqKey="Makasa M">M Makasa</name></author><author><name sortKey="Kasonka, L" uniqKey="Kasonka L">L Kasonka</name></author><author><name sortKey="Sinkala, M" uniqKey="Sinkala M">M Sinkala</name></author><author><name sortKey="Chintu, C" uniqKey="Chintu C">C Chintu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sazawal, S" uniqKey="Sazawal S">S Sazawal</name></author><author><name sortKey="Black, R" uniqKey="Black R">R Black</name></author><author><name sortKey="Ramsan, M" uniqKey="Ramsan M">M Ramsan</name></author><author><name sortKey="Chwaya, H" uniqKey="Chwaya H">H Chwaya</name></author><author><name sortKey="Stoltzfus, R" uniqKey="Stoltzfus R">R Stoltzfus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Serlemitsos, J" uniqKey="Serlemitsos J">J Serlemitsos</name></author><author><name sortKey="Fusco, H" uniqKey="Fusco H">H Fusco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramakrishnan, U" uniqKey="Ramakrishnan U">U Ramakrishnan</name></author><author><name sortKey="Nguyen, P" uniqKey="Nguyen P">P Nguyen</name></author><author><name sortKey="Martorell, R" uniqKey="Martorell R">R Martorell</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Owino, V" uniqKey="Owino V">V Owino</name></author><author><name sortKey="Sinkala, M" uniqKey="Sinkala M">M Sinkala</name></author><author><name sortKey="Amadi, B" uniqKey="Amadi B">B Amadi</name></author><author><name sortKey="Tomkins, A" uniqKey="Tomkins A">A Tomkins</name></author><author><name sortKey="Filteau, S" uniqKey="Filteau S">S Filteau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Owino, Vo" uniqKey="Owino V">VO Owino</name></author><author><name sortKey="Kasonka, Lm" uniqKey="Kasonka L">LM Kasonka</name></author><author><name sortKey="Sinkala, Mm" uniqKey="Sinkala M">MM Sinkala</name></author><author><name sortKey="Wells, Jk" uniqKey="Wells J">JK Wells</name></author><author><name sortKey="Eaton, S" uniqKey="Eaton S">S Eaton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Owino, V" uniqKey="Owino V">V Owino</name></author><author><name sortKey="Kasonka, L" uniqKey="Kasonka L">L Kasonka</name></author><author><name sortKey="Sinkala, M" uniqKey="Sinkala M">M Sinkala</name></author><author><name sortKey="Wells, J" uniqKey="Wells J">J Wells</name></author><author><name sortKey="Eaton, S" uniqKey="Eaton S">S Eaton</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Dohlman, E" uniqKey="Dohlman E">E Dohlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lehrfield, J" uniqKey="Lehrfield J">J Lehrfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lohman, T" uniqKey="Lohman T">T Lohman</name></author><author><name sortKey="Roche, A" uniqKey="Roche A">A Roche</name></author><author><name sortKey="Martorell, R" uniqKey="Martorell R">R Martorell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zerfas, A" uniqKey="Zerfas A">A Zerfas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ulijaszek, S" uniqKey="Ulijaszek S">S Ulijaszek</name></author><author><name sortKey="Kerr, D" uniqKey="Kerr D">D Kerr</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Beesley, R" uniqKey="Beesley R">R Beesley</name></author><author><name sortKey="Filteau, S" uniqKey="Filteau S">S Filteau</name></author><author><name sortKey="Tomkins, A" uniqKey="Tomkins A">A Tomkins</name></author><author><name sortKey="Doherty, T" uniqKey="Doherty T">T Doherty</name></author><author><name sortKey="Ayles, H" uniqKey="Ayles H">H Ayles</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Filmer, D" uniqKey="Filmer D">D Filmer</name></author><author><name sortKey="Pritchett, L" uniqKey="Pritchett L">L Pritchett</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lartey, A" uniqKey="Lartey A">A Lartey</name></author><author><name sortKey="Manu, A" uniqKey="Manu A">A Manu</name></author><author><name sortKey="Brown, Kh" uniqKey="Brown K">KH Brown</name></author><author><name sortKey="Peerson, Jm" uniqKey="Peerson J">JM Peerson</name></author><author><name sortKey="Dewey, Kg" uniqKey="Dewey K">KG Dewey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sun, H Y" uniqKey="Sun H">H-Y Sun</name></author><author><name sortKey="Singh, N" uniqKey="Singh N">N Singh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, H" uniqKey="Chen H">H Chen</name></author><author><name sortKey="Zhuo, Q" uniqKey="Zhuo Q">Q Zhuo</name></author><author><name sortKey="Yuan, W" uniqKey="Yuan W">W Yuan</name></author><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Wu, T" uniqKey="Wu T">T Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Safrin, S" uniqKey="Safrin S">S Safrin</name></author><author><name sortKey="Lee, B" uniqKey="Lee B">B Lee</name></author><author><name sortKey="Sande, M" uniqKey="Sande M">M Sande</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chanda, P" uniqKey="Chanda P">P Chanda</name></author><author><name sortKey="Hamainza, B" uniqKey="Hamainza B">B Hamainza</name></author><author><name sortKey="Mulenga, S" uniqKey="Mulenga S">S Mulenga</name></author><author><name sortKey="Chalwe, V" uniqKey="Chalwe V">V Chalwe</name></author><author><name sortKey="Msiska, C" uniqKey="Msiska C">C Msiska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Allen, L" uniqKey="Allen L">L Allen</name></author><author><name sortKey="De Benoist, B" uniqKey="De Benoist B">B de Benoist</name></author><author><name sortKey="Dary, O" uniqKey="Dary O">O Dary</name></author><author><name sortKey="Hurrell, R" uniqKey="Hurrell R">R Hurrell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arpadi, S" uniqKey="Arpadi S">S Arpadi</name></author><author><name sortKey="Fawzy, A" uniqKey="Fawzy A">A Fawzy</name></author><author><name sortKey="Aldrovandi, G" uniqKey="Aldrovandi G">G Aldrovandi</name></author><author><name sortKey="Kankasa, C" uniqKey="Kankasa C">C Kankasa</name></author><author><name sortKey="Sinkala, M" uniqKey="Sinkala M">M Sinkala</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fillol, F" uniqKey="Fillol F">F Fillol</name></author><author><name sortKey="Cournil, A" uniqKey="Cournil A">A Cournil</name></author><author><name sortKey="Cames, C" uniqKey="Cames C">C Cames</name></author><author><name sortKey="Sokhna, C" uniqKey="Sokhna C">C Sokhna</name></author><author><name sortKey="Simondon, Kb" uniqKey="Simondon K">KB Simondon</name></author></analytic></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20567511</article-id><article-id pub-id-type="pmc">2887362</article-id><article-id pub-id-type="publisher-id">09-PONE-RA-14295R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0011165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Pediatrics and Child Health</subject><subject>Infectious Diseases/HIV Infection and AIDS</subject><subject>Nutrition/Malnutrition</subject><subject>Public Health and Epidemiology/Global Health</subject></subj-group></article-categories><title-group><article-title>Micronutrient Fortification to Improve Growth and Health of Maternally HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial</article-title><alt-title alt-title-type="running-head">Micronutrient Fortification</alt-title></title-group><contrib-group><contrib contrib-type="author"><collab>The Chilenje Infant Growth</collab></contrib><contrib contrib-type="author"><collab>Nutrition and Infection (CIGNIS) Study Team</collab><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>¶</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Kissinger</surname><given-names>Patricia</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1">Tulane University, United States of America</aff><author-notes><corresp id="cor1">* E-mail: <email>Suzanne.Filteau@lshtm.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: TCSTN SF. Performed the experiments: TCSTN. Analyzed the data: TCSTN. Contributed reagents/materials/analysis tools: TCSTN. Wrote the paper: TCSTN SF.</p></fn><fn id="fn1" fn-type="other"><p>¶ Membership of The Chilenje Infant Growth, Nutrition and Infection (CIGNIS) Study Team is provided in the Acknowledgments.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2010</year></pub-date><volume>5</volume><issue>6</issue><elocation-id>e11165</elocation-id><history><date date-type="received"><day>17</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2010</year></date></history><permissions><copyright-statement>The Chilenje Infant Growth, Nutrition and Infection (CIGNIS) Study Team. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>The period of complementary feeding, starting around 6 months of age, is a time of high risk for growth faltering and morbidity. Low micronutrient density of locally available foods is a common problem in low income countries. Children of HIV-infected women are especially vulnerable. Although antiretroviral prophylaxis can reduce breast milk HIV transmission in early infancy, there are no clear feeding guidelines for after 6 months. There is a need for acceptable, feasible, affordable, sustainable and safe (AFASS by WHO terminology) foods for both HIV-exposed and unexposed children after 6 months of age.</p></sec><sec><title>Methods and Findings</title><p>We conducted in Lusaka, Zambia, a randomised double-blind trial of two locally made infant foods: porridges made of flour composed of maize, beans, bambaranuts and groundnuts. One flour contained a basal and the other a rich level of micronutrient fortification. Infants (n = 743) aged 6 months were randomised to receive either regime for 12 months. The primary outcome was stunting (length-for-age Z<−2) at age 18 months. No significant differences were seen between trial arms overall in proportion stunted at 18 months (adjusted odds ratio 0.87; 95% CI 0.50, 1.53; P = 0.63), mean length-for-age Z score, or rate of hospital referral or death. Among children of HIV-infected mothers who breastfed <6 months (53% of HIV-infected mothers), the richly-fortified porridge increased length-for-age and reduced stunting (adjusted odds ratio 0.17; 95% CI 0.04, 0.84; P = 0.03). Rich fortification improved iron status at 18 months as measured by hemoglobin, ferritin and serum transferrin receptors.</p></sec><sec><title>Conclusions</title><p>In the whole study population, the rich micronutrient fortification did not reduce stunting or hospital referral but did improve iron status and reduce anemia. Importantly, in the infants of HIV-infected mothers who stopped breastfeeding before 6 months, the rich fortification improved linear growth. Provision of such fortified foods may benefit health of these high risk infants.</p></sec><sec><title>Trial registration</title><p>Controlled-Trials.com <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/mrct/trial/835053/ISRCTN37460449">ISRCTN37460449</ext-link></p></sec></abstract><counts><page-count count="12"></page-count></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The period of complementary feeding is a period of high risk for growth faltering which may result in permanent stunting and its adverse health consequences. <xref ref-type="bibr" rid="pone.0011165-Shrimpton1">[1]</xref> Although there has been some progress in promoting and supporting exclusive breastfeeding, <xref ref-type="bibr" rid="pone.0011165-World1">[2]</xref> programmes addressing complementary feeding <xref ref-type="bibr" rid="pone.0011165-World2">[3]</xref> in the second half of infancy and early childhood have yet to meet with similar success.</p><p>Infant and young child feeding practices are further complicated in HIV-endemic sub-Saharan Africa. HIV-exposed infants, even if not themselves infected, are at increased risk of poor growth and death; mechanisms are unclear but likely involve nutrition <xref ref-type="bibr" rid="pone.0011165-Filteau1">[4]</xref>. HIV-infected women are advised to exclusively breastfeed their infants unless they have access to replacement foods which are acceptable, feasible, affordable, sustainable and safe (AFASS; <xref ref-type="bibr" rid="pone.0011165-World3">[5]</xref>). Recent studies have shown that providing antiretroviral drugs to women or infants for the first few months after delivery can reduce breast milk transmission of HIV <xref ref-type="bibr" rid="pone.0011165-Mofenson1">[6]</xref>. However, it remains unclear when to stop these antiretrovirals in women who do not yet need them for their own health and when HIV-infected women should stop breastfeeding. Given the continuing transmission risk throughout breastfeeding <xref ref-type="bibr" rid="pone.0011165-Mofenson1">[6]</xref>, many HIV-infected women wish to stop early, especially if their infant is HIV-negative at around 6 months old. Furthermore, after about 6 months, other foods need to be introduced to the infant's diet, whether or not the mother continues to breastfeed <xref ref-type="bibr" rid="pone.0011165-World2">[3]</xref>. Unfortunately, in much of sub-Saharan Africa available foods for infants are grossly inadequate whether they are fed as complementary foods or as replacement foods in the absence of breastfeeding <xref ref-type="bibr" rid="pone.0011165-Filteau1">[4]</xref>, <xref ref-type="bibr" rid="pone.0011165-World4">[7]</xref>, <xref ref-type="bibr" rid="pone.0011165-Lunney1">[8]</xref>.</p><p>A major problem with available infant foods is low micronutrient density. <xref ref-type="bibr" rid="pone.0011165-Dewey1">[9]</xref> Micronutrient deficiencies are common in Zambia. <xref ref-type="bibr" rid="pone.0011165-Famine1">[10]</xref>, <xref ref-type="bibr" rid="pone.0011165-Gitau1">[11]</xref> Micronutrient-rich foods are often expensive and fortification of widely consumed foods may be a more effective intervention to improve micronutrient status than promotion of consumption of foods naturally rich in micronutrients. Furthermore, central fortification requires less active consumer participation than micronutrient supplementation and is not associated with adverse effects seen with some supplements, notably iron <xref ref-type="bibr" rid="pone.0011165-Sazawal1">[12]</xref>. Zambia has a track record of successful implementation of universal fortification of sugar with vitamin A and salt with iodine. <xref ref-type="bibr" rid="pone.0011165-Famine1">[10]</xref>, <xref ref-type="bibr" rid="pone.0011165-Serlemitsos1">[13]</xref> There have been plans to fortify the staple, maize, with several micronutrients. <xref ref-type="bibr" rid="pone.0011165-Famine1">[10]</xref> However, the fortificant levels for general consumption are unlikely to meet the micronutrient needs of young children who have fast growth rates yet low food intakes. The requirements for many micronutrients in children aged 6 to 24 months are not well known and have often been extrapolated from levels consumed by healthy, older children.<xref ref-type="bibr" rid="pone.0011165-Dewey1">[9]</xref> As a result, some estimated requirements may be in excess of the true requirements and it may be unnecessarily costly to meet them. A recent meta-analysis <xref ref-type="bibr" rid="pone.0011165-Ramakrishnan1">[14]</xref> concluded that multiple micronutrient interventions had modest benefits for linear growth among primarily breastfed infants and young children but the trials have not addressed non-breastfed infants.</p><p>We have conducted a randomised, double-blind, controlled trial of the efficacy of two locally produced complementary/replacement foods, fortified with different levels of micronutrients, for infants aged 6 to 18 months. To our knowledge, this is the first study investigating AFASS foods for infants of HIV-infected mothers after 6 months, is the largest trial of multiple micronutrients for children of this age <xref ref-type="bibr" rid="pone.0011165-Ramakrishnan1">[14]</xref>, and is a relatively rare double-blind, controlled trial of a food-based intervention. Many previous studies have used supplementation approaches which are generally easier to run and control at the trial stage but use interventions which may be less easy to implement sustainably than fortification approaches.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>The trial is registered as ISRCTN37460449 (<ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/mrct">www.controlled-trials.com/mrct</ext-link>). The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0011165.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0011165.s002">Protocol S1</xref>. Children were randomised to one of two locally produced porridges at age 6 months, and were followed monthly for 12 months. The primary outcome was the prevalence of stunting at 18 months, chosen since stunting begins in early infancy, is the most common form of malnutrition in young children, is largely irreversible, and is associated with long term poor health and development. The key secondary outcome was hospital referral or death.</p></sec><sec id="s2b"><title>Study population and recruitment</title><p>The trial was conducted in Chilenje, Lusaka, Zambia, from October 2005 to July 2009. Infants were recruited by informing mothers attending the child health section of the government clinic on the same site as the project clinic. As over 90% of Lusaka women bring their infants to the clinic for monthly weighing or standard early vaccinations, <xref ref-type="bibr" rid="pone.0011165-World5">[15]</xref> the population hearing about the study was representative of the area. According to Zambian government policy, all children receive the following vitamin A supplements at these ages: 0–5 months and not breastfeeding 15 mg, all children 6–11 months 30 mg, all children 12–59 months 60 mg. Study staff arranged for the 6, 12 and 18 month doses for study children.</p><p>Infants were eligible if they were 6 months +/−2 weeks old and in generally good health and their mothers gave written consent to attend monthly clinic visits for the next year, feed their infants the allocated porridge, have their infant undergo project tests including blood and urine sampling, and have their child tested for HIV at 18 months old. Knowledge of maternal HIV status was not a requirement for joining the study but 90% of women knew their status from antenatal HIV antibody testing in the government health service using the same algorithm described below for project testing.</p></sec><sec id="s2c"><title>Randomisation</title><p>Randomisation was in blocks of 20; the code was held by the project Data Safety and Monitoring Board (DSMB). One kg bags of porridge flour were labelled with the participant ID number. At the recommendation of the DSMB, the randomisation and labelling process was audited halfway through the study by an independent observer and found to be robust, accurate and able to maintain blinding of other study staff and participants.</p><p>Infants were allotted to porridges by sequential numbers on recruitment. Twins (n = 13 pairs) were randomised to the same diet and included in analyses as separate individuals. There was one serious protocol violation: during May – June 2007 one porridge ran out but staff continued to recruit to the other treatment; the children who were thus not appropriately randomised were followed for ethical reasons but are not included in the present analyses.</p></sec><sec id="s2d"><title>Study porridges</title><p>The two flours, based on maize, beans, bambaranuts and groundnuts, were similar in bulk ingredients and macronutrient content but differed in micronutrient content (<xref ref-type="table" rid="pone-0011165-t001">Table 1</xref>). The flours were mixed with water to make porridges for infant feeding, similar in consistency and appearance to those in current local use. In pilot work, porridges were found to be acceptable <xref ref-type="bibr" rid="pone.0011165-Owino1">[16]</xref> to the local population and to displace other micronutrient-poor complementary or family foods but not to displace breast milk intake <xref ref-type="bibr" rid="pone.0011165-Owino2">[17]</xref>. The energy density of the porridge prepared according to package directions (equivalent to 30g blended in 250 ml water) was 0.76 kcal/g; <xref ref-type="bibr" rid="pone.0011165-Owino3">[18]</xref> protein represented 16% of energy. The richly fortified porridge contained micronutrients to meet the World Health Organization (WHO) estimated needs <xref ref-type="bibr" rid="pone.0011165-Dewey1">[9]</xref> for infants aged 9–11 months with low breast milk intake, assuming an intake of 50g flour/day. We did not include iodine in the micronutrient premix since Zambian salt is fortified with iodine. The basal porridge had micronutrient levels which would be produced without any additional fortificants once maize in Zambia is fortified at the planned level. <xref ref-type="bibr" rid="pone.0011165-Famine1">[10]</xref>, <xref ref-type="bibr" rid="pone.0011165-MOST1">[19]</xref> Micronutrient premixes for both flours were prepared by DSM (Isando, South Africa). Flour was mixed and processed by extrusion at Quality Commodities Ltd, Lusaka. Porridge flours were stored for up to 6 months in a cool, well-ventilated room.</p><table-wrap id="pone-0011165-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t001</object-id><label>Table 1</label><caption><title>Composition of the trial porridge flours.</title></caption><alternatives><graphic id="pone-0011165-t001-1" xlink:href="pone.0011165.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Basal fortification (per kg flour)<xref ref-type="table-fn" rid="nt101">1</xref></td><td align="left" rowspan="1" colspan="1">Rich fortification (per kg flour)<xref ref-type="table-fn" rid="nt102">2</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">maize</td><td align="left" rowspan="1" colspan="1">650 g</td><td align="left" rowspan="1" colspan="1">615 g</td></tr><tr><td align="left" rowspan="1" colspan="1">groundnuts</td><td align="left" rowspan="1" colspan="1">150 g</td><td align="left" rowspan="1" colspan="1">150 g</td></tr><tr><td align="left" rowspan="1" colspan="1">bambaranuts</td><td align="left" rowspan="1" colspan="1">50 g</td><td align="left" rowspan="1" colspan="1">50 g</td></tr><tr><td align="left" rowspan="1" colspan="1">beans (white and yellow)</td><td align="left" rowspan="1" colspan="1">150 g</td><td align="left" rowspan="1" colspan="1">150 g</td></tr><tr><td align="left" rowspan="1" colspan="1">energy</td><td align="left" rowspan="1" colspan="1">4200 kcal</td><td align="left" rowspan="1" colspan="1">4140 kcal</td></tr><tr><td align="left" rowspan="1" colspan="1">protein</td><td align="left" rowspan="1" colspan="1">15%</td><td align="left" rowspan="1" colspan="1">15%</td></tr><tr><td align="left" rowspan="1" colspan="1">fat</td><td align="left" rowspan="1" colspan="1">12%</td><td align="left" rowspan="1" colspan="1">12%</td></tr><tr><td align="left" rowspan="1" colspan="1">vitamin A</td><td align="left" rowspan="1" colspan="1">0.65 RE</td><td align="left" rowspan="1" colspan="1">6.5 RE</td></tr><tr><td align="left" rowspan="1" colspan="1">vitamin C</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">2.0 g</td></tr><tr><td align="left" rowspan="1" colspan="1">vitamin D</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0.1 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">thiamin (mononitrate)</td><td align="left" rowspan="1" colspan="1">1.3 mg</td><td align="left" rowspan="1" colspan="1">9 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">riboflavin</td><td align="left" rowspan="1" colspan="1">1.6 mg</td><td align="left" rowspan="1" colspan="1">11.2 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">niacin (niacinamide)</td><td align="left" rowspan="1" colspan="1">13 mg</td><td align="left" rowspan="1" colspan="1">140 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">pyridoxine (HCl)</td><td align="left" rowspan="1" colspan="1">1.6 mg</td><td align="left" rowspan="1" colspan="1">8.6 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">folate</td><td align="left" rowspan="1" colspan="1">0.65 mg</td><td align="left" rowspan="1" colspan="1">2.21 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">B12</td><td align="left" rowspan="1" colspan="1">3.25 µg</td><td align="left" rowspan="1" colspan="1">9.75 µg</td></tr><tr><td align="left" rowspan="1" colspan="1">pantothenic acid</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">40.3 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">magnesium (oxide)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">943 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">iron (ferrous fumarate)<xref ref-type="table-fn" rid="nt103">3</xref></td><td align="left" rowspan="1" colspan="1">6.5 mg</td><td align="left" rowspan="1" colspan="1">250 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">zinc (oxide)<xref ref-type="table-fn" rid="nt103">3</xref></td><td align="left" rowspan="1" colspan="1">9.75 mg</td><td align="left" rowspan="1" colspan="1">200 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">copper (gluconate)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3.2 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">manganese (sulfate monohydrate)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">12.0 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">selenium (sodium selenite)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">0.2 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">calcium (CaH(PO<sub>4</sub>)*2H<sub>2</sub>O)<xref ref-type="table-fn" rid="nt103">3</xref></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">6.8 g</td></tr><tr><td align="left" rowspan="1" colspan="1">phosphorus (CaH(PO<sub>4</sub>)*2H<sub>2</sub>O)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">5.3 g</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>1</label><p>Based on estimated amounts of micronutrients which would be available from 50 g porridge flour/day made with maize fortified at levels planned nationally for Zambia. Overages (usually 10%) added to allow for losses during processing.</p></fn><fn id="nt102"><label>2</label><p>Based on total estimated micronutrient needs of infants aged 9–11 months minus amounts expected from low breast milk intakes <xref ref-type="bibr" rid="pone.0011165-Dewey1">[9]</xref> and assuming intake of 50g porridge flour/day. Exceptions to the micronutrient levels are that vitamin C was increased to compensate for low iron bioavailability and zinc was based on Recommended Daily Allowance set by the International Zinc Consultative Group. <xref ref-type="bibr" rid="pone.0011165-International1">[39]</xref> Overages (usually 10%) added to allow for losses during processing.</p></fn><fn id="nt103"><label>3</label><p>Phytate was analysed in two batches of each flour and averaged 5.8 g/kg. This translated into phytate∶zinc molar ratios of ∼19 in the basal flour and ∼3.3 in the richly fortified flour and phytate∶iron molar ratios of 5.6 and 1.7 in the two flours, respectively.</p></fn></table-wrap-foot></table-wrap><p>Each batch of flour was analysed by the National Institute for Scientific and Industrial Research, Lusaka, for macronutrients by proximate analysis and for iron and zinc by flame atomic absorption spectroscopy. <xref ref-type="bibr" rid="pone.0011165-AOAC1">[20]</xref> All batches contained less than the tolerance levels of aflatoxin (<xref ref-type="bibr" rid="pone.0011165-Dohlman1">[21]</xref>; analyses by Cheetah, Zambia Ltd, Lusaka, or Polucon, Mombasa, Kenya). Several batches were also analysed for phytate by HPLC <xref ref-type="bibr" rid="pone.0011165-Lehrfield1">[22]</xref> in the laboratory of RSG at the University of Otago, New Zealand.</p></sec><sec id="s2e"><title>Follow-up and adherence</title><p>At recruitment, socio-demographic information was obtained by questionnaire. Weight, adherence, and morbidity were assessed monthly and length and other anthropometry 3-monthly in the clinic. Women were given 4 kg of porridge flour each month and could return for more as required. They were instructed to prepare the porridge according to the directions on the package, using a plastic cup, graduated in mL, supplied by the investigators. Adherence was determined through monthly questioning of mothers as to how much prepared porridge the child had consumed (in mL) within each of the two days prior to the visit and whether consumption on these days was typical. For each month the mean and standard deviation (SD) reported intake of the porridge food provided was calculated for ‘typical’ days. Infants were given adherence scores of 1 (low, <1 SD below the mean), 2 (average, ±1 SD of the mean), or 3 (high, >1 SD above the mean). Missed visits were assigned an adherence value of 1. The values for each month were added in order to calculate a cumulative adherence score.</p></sec><sec id="s2f"><title>Anthropometry</title><p>Anthropometric measurements were taken using calibrated equipment and standardized techniques, <xref ref-type="bibr" rid="pone.0011165-Lohman1">[23]</xref> with children nude or wearing a diaper. Maternal weight and height were measured at recruitment using, respectively, a digital scale (to 100 g) and wall-mounted flexible tape (to 1 mm). Infant weight was measured on a digital balance (to 10 g) and length on a length board to 1 mm (anthropometry equipment from Chasmor Ltd, London, UK). Staff conducting anthropometry were trained by RSG and AM using a repeat-measures protocol until they reached an acceptable level of proficiency. <xref ref-type="bibr" rid="pone.0011165-Zerfas1">[24]</xref> Measurement quality was maintained by achieving acceptable ranges for both the differences in measurements between the designated criterion anthropometrist (MC) and the other anthropometrists <xref ref-type="bibr" rid="pone.0011165-Zerfas1">[24]</xref> and for the total technical error of each measurement. <xref ref-type="bibr" rid="pone.0011165-Ulijaszek1">[25]</xref></p><p>All anthropometric measurements were done in triplicate and the median used in analyses. Standard deviation, Z, scores were calculated using the WHO growth reference data <xref ref-type="bibr" rid="pone.0011165-World6">[26]</xref> and the child's exact age at measurement. Stunting was considered as length/age Z<−2.</p></sec><sec id="s2g"><title>Morbidity assessments</title><p>At all scheduled and unscheduled visits the clinical officer (JS) examined children and diagnosed and treated them according to the Integrated Management of Childhood Illness. <xref ref-type="bibr" rid="pone.0011165-World7">[27]</xref> Basic care plus prescription of antibiotics or antimalarials were possible within the study clinic. Patients were referred either to Chilenje main clinic, where limited services were available, or to University Teaching Hospital (UTH), the local tertiary facility, only when exhibiting danger signs (unable to drink or breastfeed, severe vomiting, convulsions, respiratory distress, lethargic or unconscious), when requiring surgery, or when repeatedly presenting with an intractable illness which required specialist consultation. Diagnoses and treatments in hospital were determined by doctors not connected with the CIGNIS study; information about these was available to the project. Referral to hospital or specialist clinic services was a trial outcome.</p><p>Classification and treatment of illness was based on local practice. If malaria was suspected from history or clinical presentation, a blood slide was taken and malaria was diagnosed if parasites were present. Further investigations were carried out in UTH for fevers without parasites, including lumbar puncture in cases of suspected meningitis. Diarrhea was defined as at least 3 loose stools or one bulky watery stool in the past 24 hours. Pneumonia was defined as history of cough or difficulty breathing plus rapid breathing (≥50 breaths/minute for infants and ≥40 breaths/minute for older children) with or without subcostal recession.</p></sec><sec id="s2h"><title>HIV testing</title><p>Serum samples from all children at 18 months were tested for antibodies to HIV. A serial testing algorithm was used. Samples were first tested using Determine HIV 1/2 (Inverness Medical, Japan). If negative, the result is taken to be negative. If positive, a second test, Unigold HIV 1/2 (Trinity Biotech plc, Ireland), was used. If positive, the final result is positive but if negative, i.e. discordant, a third test SD-Bioline HIV 1/2 (Standard Diagnostics, Korea) was used and its result was taken to be the final result.</p></sec><sec id="s2i"><title>Iron status</title><p>Three indicators of iron status were measured at baseline and 18 months of age. Hemoglobin was measured in fingerprick blood in by Hemocue (Dronfield, UK). Venous blood was collected in plain vacutainers, sera separated at UTH within 2 hours, aliquoted and stored at −80°C. Samples were transported to London for serum ferritin and transferrin receptor (TRFR) assays. Ferritin was measured by ELISA <xref ref-type="bibr" rid="pone.0011165-Beesley1">[28]</xref> using antibodies from Insight Biotechnology Ltd (Wembley, UK) and Invitrogen Ltd (Paisley, UK) with standards from Dade Behring (Milton Keynes, UK). The interassay coefficient of variation (CV) for the standard (National Institute of Biological Standards and Control, Potters Bar, UK) was 12%. TRFR was measured by ELISA using a commercial kit (RAMCO, ATI Atlas, Chichester, UK). The interassay CVs for the high and low quality control sera were, respectively, 6.9% and 9.5%. For both assays, external quality control standards were within expected ranges.</p></sec><sec id="s2j"><title>Data management and statistics</title><p>Data were double-entered and verified in Access. Range and logical checks were run in Access and in Stata (Statacorp, College Station, TX, USA). Stata version 10 was used for all analyses. The analysis plan was finalised before the trial was unblinded.</p><p>The impact of richly-fortified porridge on stunting at 18 months (the primary endpoint) was estimated using odds ratios (OR) and 95% confidence intervals (CI) obtained by logistic regression. Length-for-age Z score was also analysed as a continuous variable with differences by linear regression. Severe morbidity, defined as hospital referral or death, was evaluated using Kaplan-Meier curves. The impact of the richly-fortified porridge on severe morbidity was estimated using hazard ratios (HR) and 95% CI obtained by Cox regression with robust standard errors to account for repeated referrals within children. Hospital referrals for planned surgeries (5 circumcisions, 4 hernias, and 4 other congenital abnormalities) were excluded from the analysis.</p><p>All analyses were stratified by maternal HIV status. The primary analyses of both outcomes were intention to treat and unadjusted. Maternal education, and socioeconomic status were considered potential confounders, and were adjusted for in secondary analyses. Socioeconomic status was measured using an asset index, created by combining data on possessions and housing characteristics using principal component analysis. <xref ref-type="bibr" rid="pone.0011165-Filmer1">[29]</xref> Since determining optimal feeding of HIV-exposed infants was a key aim of the study, analyses of children of HIV-infected mothers were stratified by breastfeeding duration.</p></sec><sec id="s2k"><title>Sample size</title><p>The sample size calculations assumed a stunting prevalence at 18 months of 40% <xref ref-type="bibr" rid="pone.0011165-World8">[30]</xref> among children receiving the basal porridge. Allowing for a 15% loss to follow up, a sample size of 400 per group was estimated to provide >90% power to detect a 30% reduction in the prevalence of stunting, and >80% power to detect a 25% reduction (alpha = 0.05). The DSMB reviewed the results twice (September 2007 and May 2008) and, after noting the prevalence of stunting was lower than anticipated and determining that an increase in sample size was financially and logistically impossible, recommended stopping recruitment in mid-July 2008.</p></sec><sec id="s2l"><title>Ethics</title><p>The study was approved by the ethics committees of the University of Zambia and the London School of Hygiene and Tropical Medicine. Mothers gave written informed consent. Project staff referred participants who were ill to local medical services and followed up treatments within these services. Neither funding source (the Bill and Melinda Gates Foundation and DSM South Africa) was involved in conduct, analysis or interpretation of the study.</p></sec></sec><sec id="s3"><title>Results</title><p>A total of 743 infants were recruited and randomised (<xref ref-type="fig" rid="pone-0011165-g001">Figure 1</xref>). There was a large number of refusals, mostly by women going away to think about it and not returning.</p><fig id="pone-0011165-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.g001</object-id><label>Figure 1</label><caption><title>Flow diagram of participants through the study.</title><p>All recruited children were included in the analysis of hospital referral and death. Two children in the richly fortified group who were seen at 18 months had missing length data at that visit and are not included in the analysis of stunting. <sup>1</sup>Reasons for withdrawal up to 12m: basal porridge (N = 46): moved away (15), family against (10), problems with porridge (2), would not say/other (19); richly fortified porridge (N = 52): moved away (18), family against (10), would not say/other (24). <sup>2</sup>Reasons for withdrawal from 12–18m: basal porridge (N = 30): moved away (13), family against (1), problems with porridge (2), would not say/other (14); richly fortified porridge (N = 27): moved away (8), family against (1), problems with porridge (1), would not say/other (17).</p></caption><graphic xlink:href="pone.0011165.g001"></graphic></fig><p>The trial arms were generally balanced at baseline (<xref ref-type="table" rid="pone-0011165-t002">Table 2</xref>). Seventy percent of mothers tested HIV-negative antenatally, 21% tested HIV-positive and 9% did not know or did not wish to disclose their status. HIV-infected women were older than uninfected women (28.5 (SD 5.4) versus 25.5 (SD 5.7) years) and were of slightly lower educational level and socioeconomic status, although the differences were not significant (data not shown). The majority (96%) of HIV-uninfected women were breastfeeding at recruitment, but 38 (24%) of HIV-infected women did not initiate breastfeeding, and an additional 50 (29%) stopped before the infant was 6 months old.</p><table-wrap id="pone-0011165-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t002</object-id><label>Table 2</label><caption><title>Description of the study population at recruitment.</title></caption><alternatives><graphic id="pone-0011165-t002-2" xlink:href="pone.0011165.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Basal porridge</td><td align="left" rowspan="1" colspan="1">Richly fortified porridge</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>N</bold></td><td align="left" rowspan="1" colspan="1">373</td><td align="left" rowspan="1" colspan="1">370</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Maternal and demographic characteristics</bold></td></tr><tr><td colspan="3" align="left" rowspan="1">Maternal antenatal HIV status<xref ref-type="table-fn" rid="nt104">1</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">261 (70%)</td><td align="left" rowspan="1" colspan="1">258 (70%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">79 (21%)</td><td align="left" rowspan="1" colspan="1">78 (21%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">33 (9%)</td><td align="left" rowspan="1" colspan="1">34 (9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mother's age (years)</td><td align="left" rowspan="1" colspan="1">26.0 (SD 5.7)</td><td align="left" rowspan="1" colspan="1">26.4 (SD 5.8)</td></tr><tr><td colspan="3" align="left" rowspan="1">Maternal body mass index (kg/m<sup>2</sup>)</td></tr><tr><td align="left" rowspan="1" colspan="1"><18.5</td><td align="left" rowspan="1" colspan="1">29 (8%)</td><td align="left" rowspan="1" colspan="1">29 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">18.5–25</td><td align="left" rowspan="1" colspan="1">225 (61%)</td><td align="left" rowspan="1" colspan="1">210 (57%)</td></tr><tr><td align="left" rowspan="1" colspan="1">25–30</td><td align="left" rowspan="1" colspan="1">76 (20%)</td><td align="left" rowspan="1" colspan="1">92 (25%)</td></tr><tr><td align="left" rowspan="1" colspan="1">>30</td><td align="left" rowspan="1" colspan="1">42 (11%)</td><td align="left" rowspan="1" colspan="1">39 (11%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Mother's education</td></tr><tr><td align="left" rowspan="1" colspan="1">primary or less</td><td align="left" rowspan="1" colspan="1">123 (33%)</td><td align="left" rowspan="1" colspan="1">129 (35%)</td></tr><tr><td align="left" rowspan="1" colspan="1">secondary</td><td align="left" rowspan="1" colspan="1">157 (42%)</td><td align="left" rowspan="1" colspan="1">127 (34%)</td></tr><tr><td align="left" rowspan="1" colspan="1">college/university</td><td align="left" rowspan="1" colspan="1">93 (25%)</td><td align="left" rowspan="1" colspan="1">114 (31%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Mother's occupation</td></tr><tr><td align="left" rowspan="1" colspan="1">housewife</td><td align="left" rowspan="1" colspan="1">214 (57%)</td><td align="left" rowspan="1" colspan="1">181 (49%)</td></tr><tr><td align="left" rowspan="1" colspan="1">salaried employee</td><td align="left" rowspan="1" colspan="1">61 (16%)</td><td align="left" rowspan="1" colspan="1">86 (23%)</td></tr><tr><td align="left" rowspan="1" colspan="1">self-employed</td><td align="left" rowspan="1" colspan="1">39 (11%)</td><td align="left" rowspan="1" colspan="1">31 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">other</td><td align="left" rowspan="1" colspan="1">59 (16%)</td><td align="left" rowspan="1" colspan="1">72 (20%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Marital status</td></tr><tr><td align="left" rowspan="1" colspan="1">married</td><td align="left" rowspan="1" colspan="1">278 (75%)</td><td align="left" rowspan="1" colspan="1">279 (75%)</td></tr><tr><td align="left" rowspan="1" colspan="1">single</td><td align="left" rowspan="1" colspan="1">79 (21%)</td><td align="left" rowspan="1" colspan="1">72 (20%)</td></tr><tr><td align="left" rowspan="1" colspan="1">divorced, separated, widowed</td><td align="left" rowspan="1" colspan="1">16 (4%)</td><td align="left" rowspan="1" colspan="1">19 (5%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Tertiles of socioeconomic status</td></tr><tr><td align="left" rowspan="1" colspan="1">low</td><td align="left" rowspan="1" colspan="1">127 (34%)</td><td align="left" rowspan="1" colspan="1">123 (33%)</td></tr><tr><td align="left" rowspan="1" colspan="1">middle</td><td align="left" rowspan="1" colspan="1">151 (40%)</td><td align="left" rowspan="1" colspan="1">136 (37%)</td></tr><tr><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1">95 (25%)</td><td align="left" rowspan="1" colspan="1">111 (30%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Infant characteristics</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (#, % F)</td><td align="left" rowspan="1" colspan="1">182 (49%)</td><td align="left" rowspan="1" colspan="1">204 (55%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Birth weight (kg)</td><td align="left" rowspan="1" colspan="1">3.05 (SD 0.50)</td><td align="left" rowspan="1" colspan="1">3.05 (SD 0.46)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight at 6 months (kg)</td><td align="left" rowspan="1" colspan="1">7.27 (SD 1.05)</td><td align="left" rowspan="1" colspan="1">7.28 (SD 1.10)</td></tr><tr><td align="left" rowspan="1" colspan="1">Length at 6 months (cm)</td><td align="left" rowspan="1" colspan="1">64.9 (SD 2.3)</td><td align="left" rowspan="1" colspan="1">64.9 (SD 2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Proportion stunted (length for age <−2 Z)</td><td align="left" rowspan="1" colspan="1">51 (14%)</td><td align="left" rowspan="1" colspan="1">40 (11%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood haemoglobin <105 g/L</td><td align="left" rowspan="1" colspan="1">140 (38%)</td><td align="left" rowspan="1" colspan="1">149 (41%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Breastfeeding duration:</td></tr><tr><td align="left" rowspan="1" colspan="1">never</td><td align="left" rowspan="1" colspan="1">22 (6%)</td><td align="left" rowspan="1" colspan="1">21 (6%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><6 months</td><td align="left" rowspan="1" colspan="1">38 (10%)</td><td align="left" rowspan="1" colspan="1">29 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">breastfeeding at recruitment</td><td align="left" rowspan="1" colspan="1">313 (84%)</td><td align="left" rowspan="1" colspan="1">320 (87%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label>1</label><p>Six infants of mothers HIV-uninfected antenatally and one of an HIV-unknown mother tested HIV-infected by 18 months old.</p></fn></table-wrap-foot></table-wrap><p>There was a 23% loss to follow-up before the infant reached 18 months. All women were contacted by study personnel to ask why they discontinued in the study. The reasons did not differ by treatment group and were: child death (12, 7%), did not want to give a reason (56, 34%), family moved from the study area (54, 32%), family opposition (22, 13%), reported problems with the study food (5, 3%), other reasons (18, 11%). There were more HIV-uninfected women among those lost to follow-up (77%) than among those who completed (68%) but these groups were otherwise very similar.</p><p>The amount of porridge consumed increased with age from ∼270 mls/d (∼19 g flour/d) at 7 months to ∼350 mls/d (∼25 g flour/d) from 11 to 18 months. Neither the number of visits attended nor adherence differed between treatment groups (OR (95% CI) for proportion of visits with high adherence in the richly-fortified compared with the basal diet: 0.79 (0.61, 1.04)). The proportion of visits with high adherence was significantly greater among children of HIV-infected women compared with HIV-uninfected women (OR (95% CI): 1.81 (1.35, 2.41)) and was significantly lower among children currently breastfed compared with those not breastfed (OR (95% CI): 0.56 (0.44, 0.70)), those in the highest socioeconomic status quintile compared with the lowest (OR (95% CI): 0.51 (0.34, 0.76)) and those whose mothers had college education compared with primary education or less (OR (95% CI): 0.63 (0.44, 0.91)).</p><p>The richly-fortified porridge increased haemoglobin between 6 and 18 months, and prevented the deterioration in iron status assessed by serum ferritin or transferrin receptors seen in the basal porridge group (<xref ref-type="table" rid="pone-0011165-t003">Table 3</xref>). Similar effects were seen for children of HIV-infected and uninfected and in those breastfed or not at recruitment (data not shown). Adherence was associated with these improvements in iron status in the richly-fortified porridge group (data not shown).</p><table-wrap id="pone-0011165-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t003</object-id><label>Table 3</label><caption><title>Indicators of iron status at 6 and 18 months of age among those who completed to 18 months<xref ref-type="table-fn" rid="nt105">1</xref>.</title></caption><alternatives><graphic id="pone-0011165-t003-3" xlink:href="pone.0011165.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td colspan="2" align="left" rowspan="1">6 Months</td><td colspan="4" align="left" rowspan="1">18 Months</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Basal porridge</td><td align="left" rowspan="1" colspan="1">Richly fortified porridge</td><td align="left" rowspan="1" colspan="1">Basal porridge</td><td align="left" rowspan="1" colspan="1">Richly fortified porridge</td><td align="left" rowspan="1" colspan="1">Unadjusted regression coefficient or Odds ratio (95% CI)</td><td align="left" rowspan="1" colspan="1">P-value</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">Haemoglobin:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">285</td><td align="left" rowspan="1" colspan="1">278</td><td align="left" rowspan="1" colspan="1">286</td><td align="left" rowspan="1" colspan="1">282</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) g/L</td><td align="left" rowspan="1" colspan="1">108 (12)</td><td align="left" rowspan="1" colspan="1">107 (14)</td><td align="left" rowspan="1" colspan="1">107 (13)</td><td align="left" rowspan="1" colspan="1">112 (11)</td><td align="left" rowspan="1" colspan="1">5.53 (3.55, 7.51)</td><td align="left" rowspan="1" colspan="1"><0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">n (%)<105 g/L</td><td align="left" rowspan="1" colspan="1">103 (36%)</td><td align="left" rowspan="1" colspan="1">115 (41%)</td><td align="left" rowspan="1" colspan="1">114 (40%)</td><td align="left" rowspan="1" colspan="1">63 (22%)</td><td align="left" rowspan="1" colspan="1">0.43 (0.30, 0.63)</td><td align="left" rowspan="1" colspan="1"><0.001</td></tr><tr><td colspan="7" align="left" rowspan="1">Serum Ferritin:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">270</td><td align="left" rowspan="1" colspan="1">264</td><td align="left" rowspan="1" colspan="1">266</td><td align="left" rowspan="1" colspan="1">262</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">median (p25, p75) µg/L</td><td align="left" rowspan="1" colspan="1">13. 2 (6.3, 24.8)</td><td align="left" rowspan="1" colspan="1">15.2 (7.8, 26.1)</td><td align="left" rowspan="1" colspan="1">8.7 (5.3, 14.2)</td><td align="left" rowspan="1" colspan="1">13.6 (9.1, 23.7)</td><td align="left" rowspan="1" colspan="1">0.49 (0.36, 0.62)</td><td align="left" rowspan="1" colspan="1"><0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">n (%)<10 µg/L</td><td align="left" rowspan="1" colspan="1">98 (36%)</td><td align="left" rowspan="1" colspan="1">80 (30%)</td><td align="left" rowspan="1" colspan="1">154 (58%)</td><td align="left" rowspan="1" colspan="1">79 (30%)</td><td align="left" rowspan="1" colspan="1">0.31 (0.22, 0.45)</td><td align="left" rowspan="1" colspan="1"><0.001</td></tr><tr><td colspan="7" align="left" rowspan="1">Serum transferrin receptor:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">267</td><td align="left" rowspan="1" colspan="1">263</td><td align="left" rowspan="1" colspan="1">271</td><td align="left" rowspan="1" colspan="1">252</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">median (p25, p75) µg/L</td><td align="left" rowspan="1" colspan="1">8.1 (6.7, 10.1)</td><td align="left" rowspan="1" colspan="1">7.9 (6.6, 9.6)</td><td align="left" rowspan="1" colspan="1">9.6 (7.9, 12.5)</td><td align="left" rowspan="1" colspan="1">7.9 (6.6, 9.6)</td><td align="left" rowspan="1" colspan="1">–0.27 (–0.33, −0.20)</td><td align="left" rowspan="1" colspan="1"><0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">n (%)>11 mg/L</td><td align="left" rowspan="1" colspan="1">48 (18%)</td><td align="left" rowspan="1" colspan="1">40 (15%)</td><td align="left" rowspan="1" colspan="1">92 (34%)</td><td align="left" rowspan="1" colspan="1">35 (14%)</td><td align="left" rowspan="1" colspan="1">0.31 (0.20, 0.49)</td><td align="left" rowspan="1" colspan="1"><0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label>1</label><p>Serum ferritin and transferrin receptor log-transformed for analysis; medians, 25<sup>th</sup> and 75<sup>th</sup> percentiles presented. Unadjusted regression coefficients and odds ratios represent overall differences between treatment arms.</p></fn></table-wrap-foot></table-wrap><p>Children of HIV-infected women had a higher prevalence of stunting at 18 months (33/133, 29%) than children of HIV-uninfected women (71/390, 18%; OR 1.80; 95% CI 1.14, 2.83; P = 0.03). Breastfeeding duration was not associated with stunting at 18 months. Children in the lowest socioeconomic group, those with mothers with only primary education, and those stunted at baseline were more likely to be stunted at 18 months (<xref ref-type="table" rid="pone-0011165-t004">Table 4</xref>). Treatment did not affect stunting or mean length-for-age Z score at 18 months overall, nor when stratified by maternal antenatal HIV status (<xref ref-type="table" rid="pone-0011165-t005">Table 5</xref>). After controlling for baseline length-for-age Z score, socioeconomic status and maternal education, indices of linear growth were significantly increased by treatment among children of HIV-infected women breastfed for less than 6 months; higher adherence was associated with greater benefit. Inclusion of only known HIV-uninfected children did not change this result.</p><table-wrap id="pone-0011165-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t004</object-id><label>Table 4</label><caption><title>Factors associated with stunting at 18 months.</title></caption><alternatives><graphic id="pone-0011165-t004-4" xlink:href="pone.0011165.t004"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">N (%)</td><td align="left" rowspan="1" colspan="1">Unadjusted OR (95% CI)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Treatment group</bold></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P = 0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Basal porridge</td><td align="left" rowspan="1" colspan="1">60/290 (20.7%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Richly-fortified porridge</td><td align="left" rowspan="1" colspan="1">57/284 (20.1%)</td><td align="left" rowspan="1" colspan="1">0.96 (0.64, 1.44)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Association with other factors</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Maternal HIV:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P = 0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">71/390 (18.2%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">38/133 (28.6%)</td><td align="left" rowspan="1" colspan="1">1.80 (1.14, 2.83)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">8/51 (15.7%)</td><td align="left" rowspan="1" colspan="1">0.84 (0.38, 1.86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Child HIV:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P = 0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">112/555 (20.2%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">4/14 (28.6%)</td><td align="left" rowspan="1" colspan="1">1.58 (0.49, 5.14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Breastfeeding duration in HIV negative mothers:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P = 0.02</td></tr><tr><td align="left" rowspan="1" colspan="1"><12 months</td><td align="left" rowspan="1" colspan="1">2/41 (4.9%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">12–17 months</td><td align="left" rowspan="1" colspan="1">37/199 (18.6%)</td><td align="left" rowspan="1" colspan="1">4.45 (1.03, 19.28)</td></tr><tr><td align="left" rowspan="1" colspan="1">18+ months</td><td align="left" rowspan="1" colspan="1">32/.150 (21.3%)</td><td align="left" rowspan="1" colspan="1">5.29 (1.21, 23.08)</td></tr><tr><td align="left" rowspan="1" colspan="1">Breastfeeding duration in HIV positive mothers:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P = 0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">8/34 (23.5%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1"><6 months</td><td align="left" rowspan="1" colspan="1">15/44 (34.1%)</td><td align="left" rowspan="1" colspan="1">1.68 (0.61, 4.61)</td></tr><tr><td align="left" rowspan="1" colspan="1">6+ months</td><td align="left" rowspan="1" colspan="1">15/55 (27.3%)</td><td align="left" rowspan="1" colspan="1">1.22 (0.45, 3.28)</td></tr><tr><td align="left" rowspan="1" colspan="1">Socioeconomic status:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P<0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">61/185 (33.0%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Middle</td><td align="left" rowspan="1" colspan="1">38/226 (16.8%)</td><td align="left" rowspan="1" colspan="1">0.41 (0.26, 0.65)</td></tr><tr><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">18/163 (11.0%)</td><td align="left" rowspan="1" colspan="1">0.25 (0.14, 0.45)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mother education:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P<0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Primary or less</td><td align="left" rowspan="1" colspan="1">63/181 (34.8%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary</td><td align="left" rowspan="1" colspan="1">38/228 (16.7%)</td><td align="left" rowspan="1" colspan="1">0.37 (0.24, 0.60)</td></tr><tr><td align="left" rowspan="1" colspan="1">College/university</td><td align="left" rowspan="1" colspan="1">16/165 (9.7%)</td><td align="left" rowspan="1" colspan="1">0.20 (0.11, 0.37)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stunted at baseline:</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">P<0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">62/501 (12.4%)</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">54/72 (75.0%)</td><td align="left" rowspan="1" colspan="1">21.25 (11.70, 38.55)</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0011165-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t005</object-id><label>Table 5</label><caption><title>Effect of porridge group on prevalence of stunting (length-for-age Z<−2) and mean length-for-age Z scores at 18 months.<xref ref-type="table-fn" rid="nt106">1</xref></title></caption><alternatives><graphic id="pone-0011165-t005-5" xlink:href="pone.0011165.t005"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Basal porridge</td><td align="left" rowspan="1" colspan="1">Richly fortified porridge</td><td align="left" rowspan="1" colspan="1">Unadjusted regression coefficient or Odds ratio (95% CI)</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">Adjusted<xref ref-type="table-fn" rid="nt107">2</xref> regression coefficient or Odds ratio (95% CI)</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>All children:</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">290</td><td align="left" rowspan="1" colspan="1">284</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">60 (20.7%)</td><td align="left" rowspan="1" colspan="1">57 (20.1%)</td><td align="left" rowspan="1" colspan="1">0.96 (0.64, 1.44)</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.87 (0.50, 1.53)</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.12 (1.11)</td><td align="left" rowspan="1" colspan="1">−1.05 (1.20)</td><td align="left" rowspan="1" colspan="1">0.08 (−0.11, 0.27)</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">0.04 (−0.07, 0.15)</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Stratified by maternal HIV status</bold><xref ref-type="table-fn" rid="nt108">3</xref><bold>:</bold></td></tr><tr><td colspan="7" align="left" rowspan="1">Negative:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">194</td><td align="left" rowspan="1" colspan="1">196</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">36 (18.6%)</td><td align="left" rowspan="1" colspan="1">35 (17.9%)</td><td align="left" rowspan="1" colspan="1">0.95 (0.57, 1.60)</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">0.92 (0.45, 1.88)</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.07 (1.04)</td><td align="left" rowspan="1" colspan="1">−0.94 (1.22)</td><td align="left" rowspan="1" colspan="1">0.14 (−0.09, 0.36)</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">0.07 (−0.06, 0.21)</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td colspan="7" align="left" rowspan="1">Positive:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">21 (30.0%)</td><td align="left" rowspan="1" colspan="1">17 (27.0%)</td><td align="left" rowspan="1" colspan="1">0.86 (0.41, 1.84)</td><td align="left" rowspan="1" colspan="1">0.70</td><td align="left" rowspan="1" colspan="1">0.41 (0.13, 1.26)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.36 (1.25)</td><td align="left" rowspan="1" colspan="1">−1.38 (1.16)</td><td align="left" rowspan="1" colspan="1">−0.02 (−0.44, 0.39)</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.17 (−0.07, 0.42)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Mother HIV positive, stratified by</bold><xref ref-type="table-fn" rid="nt108">3</xref><bold>:</bold></td></tr><tr><td colspan="7" align="left" rowspan="1">Breastfeeding <6 months:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">15 (34.9%)</td><td align="left" rowspan="1" colspan="1">8 (22.9%)</td><td align="left" rowspan="1" colspan="1">0.55 (0.20, 1.52)</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">0.17 (0.04, 0.85)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.40 (1.34)</td><td align="left" rowspan="1" colspan="1">−1.23 (1.28)</td><td align="left" rowspan="1" colspan="1">0.18 (−0.42, 0.77)</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">0.40 (0.05, 0.75)</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td colspan="7" align="left" rowspan="1">Breastfeeding ≥6 months:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">6 (22.2%)</td><td align="left" rowspan="1" colspan="1">9 (32.1%)</td><td align="left" rowspan="1" colspan="1">1.66 (0.50, 5.53)</td><td align="left" rowspan="1" colspan="1">0.41</td><td align="left" rowspan="1" colspan="1">1.10 (0.16, 7.53)</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.28 (1.13)</td><td align="left" rowspan="1" colspan="1">−1.57 (0.97)</td><td align="left" rowspan="1" colspan="1">−0.29 (−0.86, 0.28)</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">−0.04 (−0.38, 0.31)</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Mother HIV positive, child HIV negative, stratified by</bold><xref ref-type="table-fn" rid="nt108">3</xref><bold>:</bold></td></tr><tr><td colspan="7" align="left" rowspan="1">Breastfeeding <6 months:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">14 (35.2%)</td><td align="left" rowspan="1" colspan="1">8 (25.0%)</td><td align="left" rowspan="1" colspan="1">0.64 (0.23, 1.80)</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.20 (0.04, 0.98)</td><td align="left" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.36 (1.29)</td><td align="left" rowspan="1" colspan="1">−1.21 (1.34)</td><td align="left" rowspan="1" colspan="1">0.15 (−0.47, 0.77)</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">0.44 (0.08, 0.80)</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td colspan="7" align="left" rowspan="1">Breastfeeding ≥6 months:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">n (%) stunting</td><td align="left" rowspan="1" colspan="1">5 (20.0%)</td><td align="left" rowspan="1" colspan="1">9 (33.3%)</td><td align="left" rowspan="1" colspan="1">2.00 (0.56, 7.09)</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">3.61 (0.35, 37.32)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (SD) length/age Z</td><td align="left" rowspan="1" colspan="1">−1.22 (1.14)</td><td align="left" rowspan="1" colspan="1">−1.60 (0.98)</td><td align="left" rowspan="1" colspan="1">−0.39 (−0.98, 0.20)</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">−0.20 (−0.55, 0.15)</td><td align="left" rowspan="1" colspan="1">0.26</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt106"><label>1</label><p>Two children, both in the richly fortified arm, were missing length data at 18 months.</p></fn><fn id="nt107"><label>2</label><p>Adjusted for baseline (6 month) length-for-age Z score, asset index score, and maternal education.</p></fn><fn id="nt108"><label>3</label><p>No subgroup analyses are presented for HIV-unknown mothers because there were mixed reasons for lack of HIV testing. Stratification by breastfeeding duration was done only for HIV-exposed children since this is the group for which an evidence base is required for policy.</p></fn></table-wrap-foot></table-wrap><p>Twelve children died, all in hospital: 7 in the basal porridge group and 5 in the richly-fortified porridge group. Causes of death were: 4 pneumonia, 3 diarrhea, 1 tuberculosis, 1 malaria, 1 meningitis, 1 anemia, 1 choking due to epileptic convulsions. Three of those in the basal group and all 5 in the richly-fortified group had HIV-infected mothers. Only one child could be HIV-tested before death and was found positive. Nine infants of mothers HIV-infected antenatally, 6 infants of mothers negative antenatally and two infants whose mother's status was unknown tested positive themselves.</p><p>There were 69 referrals among 64 (17%) children in the basal diet group and 81 referrals among 65 (17%) children in the richly fortified diet group (<xref ref-type="table" rid="pone-0011165-t006">Table 6</xref>). In both groups, 91% of referrals were in-patient admissions. The causes of referral were similar in the two porridge groups except that there were slightly fewer for malaria (HR = 0.63; 95% CI 0.32, 1.24; p = 0.18) and significantly more for pneumonia (HR = 2.68, 95% CI = 1.17–6.11, p = 0.02) in the richly-fortified group. Trial arm had no significant effect overall on the rate of total referrals (<xref ref-type="table" rid="pone-0011165-t007">Table 7</xref> and <xref ref-type="fig" rid="pone-0011165-g002">Figure 2</xref>). Similar results were seen if time to first referral only was analysed (data not shown). There was a trend towards increased referrals among children of HIV-infected mothers in the richly-fortified group, although this did not reach statistical significance. This trend appeared to be mostly due to effects in children who were HIV-infected, but appeared independent of breastfeeding duration.</p><fig id="pone-0011165-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.g002</object-id><label>Figure 2</label><caption><title>Kaplan-Meier estimates of survivor function for hospital referral or death.</title><p>All 12 deaths occurred in hospital. Dropouts were censored at the date of last project visit. Admitted children became at risk again on discharge from hospital. In Figure 2b. ‘neg’ = HIV-uninfected mother; ‘pos’ = HIV-infected mother; HIV-unknown women are not included. There were no significant differences by treatment either overall (P = 0.31) or within maternal HIV status groups (P = 0.98 for children of HIV-negative mothers and P = 0.07 for children of HIV-positive mothers).</p></caption><graphic xlink:href="pone.0011165.g002"></graphic></fig><table-wrap id="pone-0011165-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t006</object-id><label>Table 6</label><caption><title>Hospital referrals and deaths by porridge group.</title></caption><alternatives><graphic id="pone-0011165-t006-6" xlink:href="pone.0011165.t006"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Basal diet</td><td align="left" rowspan="1" colspan="1">Richly fortified diet</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">373</td><td align="left" rowspan="1" colspan="1">370</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths (% of all children)</td><td align="left" rowspan="1" colspan="1">7 (1.9%)</td><td align="left" rowspan="1" colspan="1">5 (1.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Known HIV positive (% of all children)</td><td align="left" rowspan="1" colspan="1">9 (2.4%)</td><td align="left" rowspan="1" colspan="1">8 (2.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Children with 1 or more referrals:</td><td align="left" rowspan="1" colspan="1">64 (17.2%)</td><td align="left" rowspan="1" colspan="1">65 (17.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of referrals<xref ref-type="table-fn" rid="nt109">1</xref></td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">81</td></tr><tr><td colspan="3" align="left" rowspan="1">Diagnoses (total referrals, % of referrals; % of all children<xref ref-type="table-fn" rid="nt110">2</xref>)</td></tr><tr><td colspan="3" align="left" rowspan="1">All children:</td></tr><tr><td align="left" rowspan="1" colspan="1">Malaria</td><td align="left" rowspan="1" colspan="1">24 (34.8%; 5.9%)</td><td align="left" rowspan="1" colspan="1">15 (18.5%; 3.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute diarrhea</td><td align="left" rowspan="1" colspan="1">16 (23.2%; 4.3%)</td><td align="left" rowspan="1" colspan="1">17 (21.0%; 4.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="left" rowspan="1" colspan="1">8 (11.6%; 2.1%)</td><td align="left" rowspan="1" colspan="1">21 (25.9%; 5.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin infections</td><td align="left" rowspan="1" colspan="1">3 (4.4%; 0.8%)</td><td align="left" rowspan="1" colspan="1">6 (7.4%; 1.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other<xref ref-type="table-fn" rid="nt111">3</xref></td><td align="left" rowspan="1" colspan="1">18 (26.1%; 4.6%)</td><td align="left" rowspan="1" colspan="1">22 (27.2%; 4.9%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Children of HIV-uninfected women<xref ref-type="table-fn" rid="nt112">4</xref>:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">261</td><td align="left" rowspan="1" colspan="1">258</td></tr><tr><td align="left" rowspan="1" colspan="1">Children with 1 or more referrals</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of referrals</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">Malaria</td><td align="left" rowspan="1" colspan="1">15 (32.6%; 5.0%)</td><td align="left" rowspan="1" colspan="1">5 (11.1%; 1.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute diarrhea</td><td align="left" rowspan="1" colspan="1">13 (28.3%; 5.0%)</td><td align="left" rowspan="1" colspan="1">11 (24.4%; 4.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="left" rowspan="1" colspan="1">5 (10.9%; 1.9%)</td><td align="left" rowspan="1" colspan="1">11 (24.4%; 4.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin infections</td><td align="left" rowspan="1" colspan="1">1 (2.2%; 0.4%)</td><td align="left" rowspan="1" colspan="1">3 (6.7%; 1.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other<xref ref-type="table-fn" rid="nt111">3</xref></td><td align="left" rowspan="1" colspan="1">12 (26.1%; 4.2%)</td><td align="left" rowspan="1" colspan="1">15 (33.3%; 4.7%)</td></tr><tr><td colspan="3" align="left" rowspan="1">Children of HIV-infected women<xref ref-type="table-fn" rid="nt112">4</xref>:</td></tr><tr><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">78</td></tr><tr><td align="left" rowspan="1" colspan="1">Children with 1 or more referrals</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">Total number of referrals</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">Malaria</td><td align="left" rowspan="1" colspan="1">6 (31.6%; 7.6%)</td><td align="left" rowspan="1" colspan="1">8 (25.0%; 9.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute diarrhea</td><td align="left" rowspan="1" colspan="1">3 (15.8%; 3.8%)</td><td align="left" rowspan="1" colspan="1">6 (18.7%; 6.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia</td><td align="left" rowspan="1" colspan="1">3 (15.8%; 3.8%)</td><td align="left" rowspan="1" colspan="1">8 (25.0%; 7.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin infections</td><td align="left" rowspan="1" colspan="1">1 (5.3%; 1.3%)</td><td align="left" rowspan="1" colspan="1">3 (9.4%; 2.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other<xref ref-type="table-fn" rid="nt111">3</xref></td><td align="left" rowspan="1" colspan="1">6 (31.6%; 7.6%)</td><td align="left" rowspan="1" colspan="1">7 (21.9%; 7.7%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label>1</label><p>Includes 137 inpatient hospital admissions and 13 (6 in the basal group and 7 in the richly-fortified group) referrals to specialist outpatient clinics.</p></fn><fn id="nt110"><label>2</label><p>Percent of children with at least one referral for each diagnosis. Note total number of referrals includes instances of more than one referral in some children.</p></fn><fn id="nt111"><label>3</label><p>Includes other infections, severe anemia, accidental injury and congenital conditions but excludes elective surgery.</p></fn><fn id="nt112"><label>4</label><p>No subgroup analyses are presented for HIV-unknown mothers because there were mixed reasons for lack of HIV testing.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0011165-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0011165.t007</object-id><label>Table 7</label><caption><title>Hazard ratios for referral to hospital or death; richly-fortified porridge group compared to basal porridge group<xref ref-type="table-fn" rid="nt113">1</xref>.</title></caption><alternatives><graphic id="pone-0011165-t007-7" xlink:href="pone.0011165.t007"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"></td><td colspan="2" align="left" rowspan="1">Referrals/person-yrs (rate per 100 pyrs)</td><td align="left" rowspan="1" colspan="1">HR (95% CI)</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Basal porridge</td><td align="left" rowspan="1" colspan="1">Richly fortified porridge</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>All children</bold></td><td align="left" rowspan="1" colspan="1">69/322 (21.4)</td><td align="left" rowspan="1" colspan="1">81/318 (25.5)</td><td align="left" rowspan="1" colspan="1">1.19 (0.85, 1.68)</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Stratified by:</bold></td></tr><tr><td colspan="5" align="left" rowspan="1">Maternal HIV status<xref ref-type="table-fn" rid="nt113">1</xref>:</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">46/219 (21.0)</td><td align="left" rowspan="1" colspan="1">45/217 (20.8)</td><td align="left" rowspan="1" colspan="1">0.99 (0.65, 1.52)</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">19/75 (25.5)</td><td align="left" rowspan="1" colspan="1">32/72 (44.8)</td><td align="left" rowspan="1" colspan="1">1.76 (0.95, 3.26)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>HIV-positive mothers, stratified by:</bold></td></tr><tr><td colspan="5" align="left" rowspan="1">Child HIV status:</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">14/66.2 (21.1)</td><td align="left" rowspan="1" colspan="1">14/59.7 (23.5)</td><td align="left" rowspan="1" colspan="1">1.12 (0.55, 2.29)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive or unknown<xref ref-type="table-fn" rid="nt115">3</xref></td><td align="left" rowspan="1" colspan="1">5/8.3 (60.3)</td><td align="left" rowspan="1" colspan="1">18/11.8 (152.5)</td><td align="left" rowspan="1" colspan="1">2.45 (0.87, 6.90)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td colspan="5" align="left" rowspan="1">Breastfeeding duration<xref ref-type="table-fn" rid="nt114">2</xref>:</td></tr><tr><td align="left" rowspan="1" colspan="1"><6 months</td><td align="left" rowspan="1" colspan="1">11/45.8 (24.0)</td><td align="left" rowspan="1" colspan="1">14/37.7 (37.2)</td><td align="left" rowspan="1" colspan="1">1.56 (0.70, 3.50)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">≥6 months</td><td align="left" rowspan="1" colspan="1">8/28.7 (27.9)</td><td align="left" rowspan="1" colspan="1">18/33.8 (53.2)</td><td align="left" rowspan="1" colspan="1">1.92 (0.75, 4.90)</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>HIV-negative children of positive mothers, stratified by:</bold></td></tr><tr><td colspan="5" align="left" rowspan="1">Breastfeeding duration<xref ref-type="table-fn" rid="nt114">2</xref>:</td></tr><tr><td align="left" rowspan="1" colspan="1"><6 months</td><td align="left" rowspan="1" colspan="1">7/42.2 (16.6)</td><td align="left" rowspan="1" colspan="1">8/32.6 (24.5)</td><td align="left" rowspan="1" colspan="1">1.50 (0.57, 4.00)</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">≥6 months</td><td align="left" rowspan="1" colspan="1">7/24.0 (29.2)</td><td align="left" rowspan="1" colspan="1">6/27.0 (22.2)</td><td align="left" rowspan="1" colspan="1">0.76 (0.27, 2.14)</td><td align="left" rowspan="1" colspan="1">0.60</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt113"><label>1</label><p>No subgroup analyses are presented for HIV-unknown mothers because there were mixed reasons for lack of HIV testing.</p></fn><fn id="nt114"><label>2</label><p>Stratification by breastfeeding duration was done only for HIV-exposed children since this is the group for which an evidence base is required for policy.</p></fn><fn id="nt115"><label>3</label><p>HIV status could not be determined for most children who died and for those who did not complete the study; they are included in the HIV-positive or unknown group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4"><title>Discussion</title><p>Provision from ages 6 to 18 months of a micronutrient-rich fortified porridge flour, formulated to meet all nutritional requirements according to current best estimates <xref ref-type="bibr" rid="pone.0011165-Dewey1">[9]</xref> was successful in improving children's iron status. This translated into modest improvements in linear growth amongst the subgroup of children of HIV-infected mothers who stopped breastfeeding before 6 months but had no effect on linear growth or hospital referral of the group as a whole. Among children of HIV-infected mothers, there was a non-significant trend towards increased referrals in the richly-fortified arm.</p><p>The population has clear evidence of deficiencies in iron and vitamin A, as determined in this and previous work <xref ref-type="bibr" rid="pone.0011165-Gitau1">[11]</xref>. Therefore, an effect of the richly-fortified porridge on iron status is important. It is interesting that this was achieved even though children's intake of porridge was only about half the estimate used for determining the micronutrient levels in the richly-fortified porridge. The porridge was also generally prepared more dilute than given in the instructions but, based on the pilot study for the trial <xref ref-type="bibr" rid="pone.0011165-Owino2">[17]</xref>, calories were not the limiting factor in these children's diets and increasing porridge energy density using α-amylase did not affect growth.</p><p>All children were provided with porridge and medical care which could be why the overall stunting rate was lower than the 40% <xref ref-type="bibr" rid="pone.0011165-World8">[30]</xref> used in sample size estimates. This 40% rate is consistent with the 36% stunting we measured among Chilenje clinic children aged 18 months who were not part of the CIGNIS study because they reached 6 months old before the recruitment period but were otherwise similar. The risk of stunting among study children compared with clinic children was: OR 0.46; 95% CI 0.25, 0.87; P = 0.007. Therefore, effects of rich fortification, compared with basal, on stunting may have been hard to detect. This problem has been seen in other food-based intervention trials <xref ref-type="bibr" rid="pone.0011165-Lartey1">[31]</xref> in low income countries where providing the control group with food is essential both ethically and logistically, i.e. to ensure equivalent compliance between groups. Low stunting prevalence could also have resulted from biased recruitment due to a refusal rate which was higher than expected, based on our previous study in Chilenje. However, we determined that birth weights of CIGNIS children were virtually identical to those of the total population of infants born in Chilenje clinic during the same period (data not shown).</p><p>Importantly, the overall rate of hospital referral plus death did not differ between treatment groups. In the richly-fortified porridge group, there were no mortalities among infants of HIV-negative mothers. Among HIV-exposed children, there was a non-significant trend toward increased referrals in the richly-fortified group, with only pneumonia referrals increased. The subgroup analysis by maternal HIV status was planned because of its policy relevance but numbers were small; thus, the trend may be from chance and should be interpreted with caution. If not chance, possible explanatory factors include: an immune reconstitution syndrome <xref ref-type="bibr" rid="pone.0011165-Sun1">[32]</xref> which could lead to increased respiratory symptoms; increased respiratory symptoms as have been previously observed following vitamin A supplementation <xref ref-type="bibr" rid="pone.0011165-Chen1">[33]</xref> but not fortification; folate antagonism of the cotrimoxazole <xref ref-type="bibr" rid="pone.0011165-Safrin1">[34]</xref> which the all children of HIV-infected mothers were given as standard of care; operational issues regarding differential diagnoses resulting from improved prevention and treatment of malaria. <xref ref-type="bibr" rid="pone.0011165-Chanda1">[35]</xref> Adverse effects of iron on malaria, as reported with iron supplementation of Tanzanian children, <xref ref-type="bibr" rid="pone.0011165-Sazawal1">[12]</xref> are unlikely since there were fewer malaria referrals for children given the richly-fortified porridge. Other infections may also be increased following iron supplementation of non-deficient children <xref ref-type="bibr" rid="pone.0011165-Sazawal1">[12]</xref> but we are not aware of studies showing increased illness with iron fortification. Since micronutrient fortification is a key part of prevention of micronutrient deficiencies globally,<xref ref-type="bibr" rid="pone.0011165-Allen1">[36]</xref> factors leading to hospital referral among this population are important and are under further investigation.</p><p>Although antiretroviral prophylaxis can reduce HIV transmission during early lactation <xref ref-type="bibr" rid="pone.0011165-Mofenson1">[6]</xref> and although HIV-infected infants should continue breastfeeding <xref ref-type="bibr" rid="pone.0011165-World3">[5]</xref>, optimal feeding practises for HIV-exposed, uninfected infants over 6 months is a current concern for policy and practice. In our study, among middle class urban HIV-infected women with access to treated water and good medical care, there was no overall effect of breastfeeding after 6 months on stunting. Provision of the richly-fortified porridge improved linear growth among non-breastfed infants of HIV-infected mothers. A recently published study also from Lusaka found growth faltering, as measured by weight-for-age, among children whose HIV-infected mothers stopped breastfeeding early but no such faltering as measured by length-for-age. <xref ref-type="bibr" rid="pone.0011165-Arpadi1">[37]</xref> Given the effects on linear growth we found among HIV-exposed children breastfed <6 months, it is likely relevant that we used considerably higher fortificant levels for the richly-fortified porridge than were in the maize blend cereal provided in the other study.</p><p>In summary, the rich micronutrient fortification did not reduce stunting or hospital referral but did improve iron status and reduce anemia. For the large proportion of HIV-infected mothers who stopped breastfeeding before 6 months, the richly micronutrient-fortified porridge may be a choice which could benefit their children's linear growth. However, the major effects on stunting appear to have resulted from factors, possibly improved health care, associated with participation in the study, as has been seen elsewhere <xref ref-type="bibr" rid="pone.0011165-Fillol1">[38]</xref>, not from higher intake of micronutrients.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0011165.s001"><label>Checklist S1</label><caption><p>CONSORT checklist.</p><p>(0.11 MB PDF)</p></caption><media xlink:href="pone.0011165.s001.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0011165.s002"><label>Protocol S1</label><caption><p>Trial Protocol.</p><p>(0.06 MB PDF)</p></caption><media xlink:href="pone.0011165.s002.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are grateful to Quality Commodities, Lusaka, especially production manager, Mr. Chongo, for preparing and storing the flours; to the Data Safety and Monitoring Board – Dr. Paul Kelly, Dr. Jim Todd, Dr. Nigel Rollins – for their considered efforts to monitor and support the trial; to Max Katubulushi, UTH, for audit of the diet randomisation and distribution processes, and to Gabi Meineke, LSHTM, for help with financial and logistic management. We are particularly grateful to the mothers and children who participated in the study and to the staff of Lusaka District Health who permitted and supported the study.</p><p>The members of the CIGNIS study team are:</p><p><underline>Principal Investigator</underline>: Suzanne Filteau, London School of Hygiene and Tropical Medicine (LSHTM), UK;</p><p><underline>Zambian Lead Investigator</underline>: Lackson Kasonka, University Teaching Hospital (UTH), Lusaka, Zambia;</p><p><underline>Senior Investigators</underline>: Rosalind Gibson, University of Otago, New Zealand; Ursula A. Gompels, LSHTM; Shabbar Jaffar, LSHTM; Emmanuel Kafwembe, Tropical Diseases Research Centre, Ndola; Mwaka Monze, UTH; Moses Sinkala, Catholic Relief Services, Zambia; Andrew Tomkins, Institute of Child Health, University College, London, UK; Rodah Zulu, National Institute of Science and Industrial Research, Lusaka, Zambia;</p><p><underline>Clinic Coordinator</underline>: Molly Chisenga;</p><p><underline>Clinical Officer</underline>: Joshua Siame;</p><p><underline>Data Manager:</underline> Hildah Banda Mabuda;</p><p><underline>Statisticians</underline>: Kathy Baisley, Helen Dale, Andrea Rehman;</p><p><underline>Research Fellows</underline>: Matthew Bates, Anne Mullen;</p><p><underline>Clinic Staff</underline>: Hellen Kangwa Bwalya, Margaret Chileshe, Priscilla Kangwa Kowa, Mabvuto Kumwenda, Munalula Likando, Sydney Mambwe, Mutinta Muzyamba, Anne Mwale, Lungowe Nyaywa;</p><p><underline>Laboratory Staff</underline>: Mirriam Kapambwe, Humphrey Bima, Laura Gosset, Louise Hackett, Abigail Jackson, Eric Njunju, Sydney Mwanza;</p><p><underline>Data Entry</underline>: Natalia Shampwaya, Concillia Kabanga;</p><p><underline>Drivers and Cleaners</underline>: John Chobo, Winford Kapumba, Charity Musonda, Philip Soko.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Main funder: Bill and Melinda Gates Foundation grant #37253. Contibution in kind (micronutrient premixes): DSM South Africa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0011165-Shrimpton1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrimpton</surname><given-names>R</given-names></name><name><surname>Victora</surname><given-names>C</given-names></name><name><surname>de Onis</surname><given-names>M</given-names></name><name><surname>Lima</surname><given-names>R</given-names></name><name><surname>Blössner</surname><given-names>M</given-names></name><etal></etal></person-group><year>2001</year><article-title>Worldwide timing of growth faltering: implications for nutritional interventions.</article-title><source>Pediatrics</source><volume>107</volume><fpage>e75</fpage><pub-id pub-id-type="pmid">11331725</pub-id></mixed-citation></ref><ref id="pone.0011165-World1"><label>2</label><mixed-citation publication-type="other"><collab>World Health Organization</collab><year>2001</year><comment>The optimal duration of exclusive breastfeeding</comment></mixed-citation></ref><ref id="pone.0011165-World2"><label>3</label><mixed-citation publication-type="other"><collab>World Health Organization</collab><year>2002</year><comment>Complementary feeding: Summary of guiding principles for complementary feeding of the breastfed child</comment></mixed-citation></ref><ref id="pone.0011165-Filteau1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filteau</surname><given-names>S</given-names></name></person-group><year>2009</year><article-title>The HIV-exposed, uninfected African child.</article-title><source>Trop Med Int Health</source><volume>14</volume><fpage>276</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">19171011</pub-id></mixed-citation></ref><ref id="pone.0011165-World3"><label>5</label><mixed-citation publication-type="other"><collab>World Health Organization</collab><year>2007</year><comment>HIV and infant feeding: update</comment></mixed-citation></ref><ref id="pone.0011165-Mofenson1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mofenson</surname><given-names>L</given-names></name></person-group><year>2009</year><article-title>Prevention of breast milk transmission of HIV: the time is now.</article-title><source>JAIDS</source><volume>52</volume><fpage>305</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">19726999</pub-id></mixed-citation></ref><ref id="pone.0011165-World4"><label>7</label><mixed-citation publication-type="other"><collab>World Health Organization</collab><year>2005</year><comment>Guiding principles for feeding non-breastfed children 6–24 months of age</comment></mixed-citation></ref><ref id="pone.0011165-Lunney1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunney</surname><given-names>K</given-names></name><name><surname>Jenkins</surname><given-names>A</given-names></name><name><surname>Tavengwa</surname><given-names>N</given-names></name><name><surname>Majo</surname><given-names>F</given-names></name><name><surname>Chidhanguro</surname><given-names>D</given-names></name><etal></etal></person-group><year>2008</year><article-title>HIV-positive poor women may stop breast-feeding early to protect their infants from HIV infection although available replacement diets are grossly inadequate.</article-title><source>J Nutr</source><volume>138</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">18203903</pub-id></mixed-citation></ref><ref id="pone.0011165-Dewey1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewey</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group><year>2003</year><article-title>Update on technical issues concerning complementary feeding of young children in developing countries and implications for intervention programs. Special issue based on a World Health Organization expert consultation on complementary feeding.</article-title><source>Food Nutr Bull</source><volume>24</volume><fpage>5</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12664525</pub-id></mixed-citation></ref><ref id="pone.0011165-Famine1"><label>10</label><mixed-citation publication-type="other"><collab>Famine Early Warning Systems Network</collab><year>2006</year><comment>Zambia Food Security Update</comment></mixed-citation></ref><ref id="pone.0011165-Gitau1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitau</surname><given-names>R</given-names></name><name><surname>Makasa</surname><given-names>M</given-names></name><name><surname>Kasonka</surname><given-names>L</given-names></name><name><surname>Sinkala</surname><given-names>M</given-names></name><name><surname>Chintu</surname><given-names>C</given-names></name><etal></etal></person-group><year>2005</year><article-title>Maternal micronutrient status and decreased growth of Zambian infants born during and after the maize price increases resulting from the Southern African drought of 2001–2002.</article-title><source>Pub Health Nutr</source><volume>8</volume><fpage>837</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">16277799</pub-id></mixed-citation></ref><ref id="pone.0011165-Sazawal1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sazawal</surname><given-names>S</given-names></name><name><surname>Black</surname><given-names>R</given-names></name><name><surname>Ramsan</surname><given-names>M</given-names></name><name><surname>Chwaya</surname><given-names>H</given-names></name><name><surname>Stoltzfus</surname><given-names>R</given-names></name><etal></etal></person-group><year>2006</year><article-title>Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial.</article-title><source>Lancet</source><volume>367</volume></mixed-citation></ref><ref id="pone.0011165-Serlemitsos1"><label>13</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Serlemitsos</surname><given-names>J</given-names></name><name><surname>Fusco</surname><given-names>H</given-names></name></person-group><year>2001</year><comment>Vitamin A Fortification of Sugar in Zambia 1998–2001</comment></mixed-citation></ref><ref id="pone.0011165-Ramakrishnan1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishnan</surname><given-names>U</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Martorell</surname><given-names>R</given-names></name></person-group><year>2009</year><article-title>Effects of micronutrients on growth of children under 5y of age: meta-analyses of single and multiple nutrient interventions.</article-title><source>Am J Clin Nutr</source><volume>89</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">19056559</pub-id></mixed-citation></ref><ref id="pone.0011165-World5"><label>15</label><mixed-citation publication-type="other"><collab>World Health Organization, UNICEF</collab><year>2009</year><comment>Review of National Immunization Coverage 1980–2008: Zambia</comment></mixed-citation></ref><ref id="pone.0011165-Owino1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owino</surname><given-names>V</given-names></name><name><surname>Sinkala</surname><given-names>M</given-names></name><name><surname>Amadi</surname><given-names>B</given-names></name><name><surname>Tomkins</surname><given-names>A</given-names></name><name><surname>Filteau</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Acceptability, storage stability and costing of alpha-amylase-treated maize-beans-groundnuts-bambaranuts complementary blend.</article-title><source>J Sci Food Agriculture</source><volume>87</volume><fpage>1021</fpage><lpage>1029</lpage></mixed-citation></ref><ref id="pone.0011165-Owino2"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owino</surname><given-names>VO</given-names></name><name><surname>Kasonka</surname><given-names>LM</given-names></name><name><surname>Sinkala</surname><given-names>MM</given-names></name><name><surname>Wells</surname><given-names>JK</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><etal></etal></person-group><year>2007</year><article-title>Fortified complementary foods with or without alpha-amylase treatment increase hemoglobin but do not reduce breast milk intake of 9-mo-old Zambian infants.</article-title><source>Am J Clin Nutr</source><volume>86</volume><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">17921388</pub-id></mixed-citation></ref><ref id="pone.0011165-Owino3"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owino</surname><given-names>V</given-names></name><name><surname>Kasonka</surname><given-names>L</given-names></name><name><surname>Sinkala</surname><given-names>M</given-names></name><name><surname>Wells</surname><given-names>J</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><etal></etal></person-group><year>2007</year><article-title>Fortified complementary foods, with or without α-amylase-treatment, increase hemoglobin but do not reduce breast milk intake of 9-month old Zambian infants.</article-title><source>Am J Clin Nutr</source><volume>86</volume><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">17921388</pub-id></mixed-citation></ref><ref id="pone.0011165-MOST1"><label>19</label><mixed-citation publication-type="other"><collab>MOST</collab><year>2005</year><comment>Fortification Basics: <ext-link ext-link-type="uri" xlink:href="http://www.mostproject.org/Updates_Feb05/Maize_Corn.pdf">maize flour/meal</ext-link></comment></mixed-citation></ref><ref id="pone.0011165-AOAC1"><label>20</label><mixed-citation publication-type="book"><collab>AOAC</collab><year>1995</year><source>Official Methods of Analysis (16th edn)</source><publisher-loc>Arlington, USA</publisher-loc><publisher-name>AOAC. International</publisher-name></mixed-citation></ref><ref id="pone.0011165-Dohlman1"><label>21</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Dohlman</surname><given-names>E</given-names></name></person-group><year>2003</year><article-title>Mycotoxin Hazards and Regulations: Impacts on Food and Animal Feed Crop Trade.</article-title><person-group person-group-type="editor"><name><surname>Jean Buzby</surname><given-names>e</given-names></name></person-group><comment>International Trade and Food Safety: Economic Theory and Case Studies; Agricultural Economic Report 828: USDA</comment></mixed-citation></ref><ref id="pone.0011165-Lehrfield1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrfield</surname><given-names>J</given-names></name></person-group><year>1989</year><article-title>High-performance liquid chromatography analysis of phytic acid on a pH-stable, macroporous polymer column.</article-title><source>Cereal Chemistry</source><volume>66</volume><fpage>510</fpage><lpage>515</lpage></mixed-citation></ref><ref id="pone.0011165-Lohman1"><label>23</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lohman</surname><given-names>T</given-names></name><name><surname>Roche</surname><given-names>A</given-names></name><name><surname>Martorell</surname><given-names>R</given-names></name></person-group><year>1988</year><source>Anthropometric standardization reference manual</source><publisher-loc>Champaign, USA</publisher-loc><publisher-name>Human Kinetics Publications</publisher-name></mixed-citation></ref><ref id="pone.0011165-Zerfas1"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zerfas</surname><given-names>A</given-names></name></person-group><year>1985</year><source>Checking continuous measures: Manual for Anthropometry</source><publisher-loc>Los Angeles, USA</publisher-loc><publisher-name>Division of epidemiology, School of Public Health, University of California</publisher-name></mixed-citation></ref><ref id="pone.0011165-Ulijaszek1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulijaszek</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name></person-group><year>1999</year><article-title>Anthropometric measurement error and the assessment of nutritional status.</article-title><source>Br J Nutr</source><volume>82</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">10655963</pub-id></mixed-citation></ref><ref id="pone.0011165-World6"><label>26</label><mixed-citation publication-type="other"><collab>World Health Organization</collab><year>2006</year><comment>Child growth standards</comment></mixed-citation></ref><ref id="pone.0011165-World7"><label>27</label><mixed-citation publication-type="book"><collab>World Health Organization</collab><year>1998</year><source>IMCI information packet</source><publisher-loc>Geneva</publisher-loc><publisher-name>Department of Child and Adolescent Health and Development, WHO/CHS/CAH/98.1D. Geneva: WHO</publisher-name></mixed-citation></ref><ref id="pone.0011165-Beesley1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beesley</surname><given-names>R</given-names></name><name><surname>Filteau</surname><given-names>S</given-names></name><name><surname>Tomkins</surname><given-names>A</given-names></name><name><surname>Doherty</surname><given-names>T</given-names></name><name><surname>Ayles</surname><given-names>H</given-names></name><etal></etal></person-group><year>2000</year><article-title>Impact of acute malaria on plasma transferrin receptor concentrations.</article-title><source>Trans Roy Soc Trop Med Hyg</source><volume>94</volume><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">10975004</pub-id></mixed-citation></ref><ref id="pone.0011165-Filmer1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filmer</surname><given-names>D</given-names></name><name><surname>Pritchett</surname><given-names>L</given-names></name></person-group><year>2001</year><article-title>Estimating wealth effects without expenditure data – or tears: an application to educational enrolments in states of India.</article-title><source>Demography</source><volume>38</volume><fpage>115</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">11227840</pub-id></mixed-citation></ref><ref id="pone.0011165-World8"><label>30</label><mixed-citation publication-type="other"><collab>World Health Organization</collab><year>2002</year><comment>Online statistics</comment></mixed-citation></ref><ref id="pone.0011165-Lartey1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lartey</surname><given-names>A</given-names></name><name><surname>Manu</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>KH</given-names></name><name><surname>Peerson</surname><given-names>JM</given-names></name><name><surname>Dewey</surname><given-names>KG</given-names></name></person-group><year>1999</year><article-title>A randomized, community-based trial of the effects of improved, centrally processed complementary foods on growth and micronutrient status of Ghanaian infants from 6 to 12 mo of age.</article-title><source>Am J Clin Nutr</source><volume>70</volume><fpage>391</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">10479202</pub-id></mixed-citation></ref><ref id="pone.0011165-Sun1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H-Y</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><year>2009</year><article-title>Immune reconstitution inflammatory syndrome in non_HIV immunocompromised patients.</article-title><source>Curr Opinion Infect Dis</source><volume>22</volume><fpage>394</fpage><lpage>402</lpage></mixed-citation></ref><ref id="pone.0011165-Chen1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhuo</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name></person-group><year>2008</year><article-title>Vitamin A for preventing acute lower respiratory tract infections in children up to seven years of age.</article-title><source>Cochrane Database Syst Rev</source><fpage>CD006090</fpage><pub-id pub-id-type="pmid">18254093</pub-id></mixed-citation></ref><ref id="pone.0011165-Safrin1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safrin</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Sande</surname><given-names>M</given-names></name></person-group><year>1994</year><article-title>Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death.</article-title><source>J Infect Dis</source><volume>170</volume><fpage>912</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">7930736</pub-id></mixed-citation></ref><ref id="pone.0011165-Chanda1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanda</surname><given-names>P</given-names></name><name><surname>Hamainza</surname><given-names>B</given-names></name><name><surname>Mulenga</surname><given-names>S</given-names></name><name><surname>Chalwe</surname><given-names>V</given-names></name><name><surname>Msiska</surname><given-names>C</given-names></name><etal></etal></person-group><year>2009</year><article-title>Early results of integrated malaria control and implications for the management of fever in under-five children at a peripheral health facility: a case study of Chongwe rural health centre in Zambia.</article-title><source>Malaria Journal</source><fpage>49</fpage><pub-id pub-id-type="pmid">19292919</pub-id></mixed-citation></ref><ref id="pone.0011165-Allen1"><label>36</label><mixed-citation publication-type="other"><person-group person-group-type="editor"><name><surname>Allen</surname><given-names>L</given-names></name><name><surname>de Benoist</surname><given-names>B</given-names></name><name><surname>Dary</surname><given-names>O</given-names></name><name><surname>Hurrell</surname><given-names>R</given-names></name></person-group><year>2006</year><comment>Guidelines on food fortification with micronutrients: World Health Organization, Food and Agriculture Organization</comment></mixed-citation></ref><ref id="pone.0011165-Arpadi1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arpadi</surname><given-names>S</given-names></name><name><surname>Fawzy</surname><given-names>A</given-names></name><name><surname>Aldrovandi</surname><given-names>G</given-names></name><name><surname>Kankasa</surname><given-names>C</given-names></name><name><surname>Sinkala</surname><given-names>M</given-names></name><etal></etal></person-group><year>2009</year><article-title>Growth faltering due to breastfeeding cessation in uninfected children born to HIV-infected mothers in Zambia.</article-title><source>Am J Clin Nutr</source><volume>90</volume><fpage>344</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">19553300</pub-id></mixed-citation></ref><ref id="pone.0011165-Fillol1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillol</surname><given-names>F</given-names></name><name><surname>Cournil</surname><given-names>A</given-names></name><name><surname>Cames</surname><given-names>C</given-names></name><name><surname>Sokhna</surname><given-names>C</given-names></name><name><surname>Simondon</surname><given-names>KB</given-names></name></person-group><year>2010</year><article-title>Active malaria morbidity management has limited impact on height status of preschool senegalese children.</article-title><source>J Nutr</source><volume>140</volume><fpage>625</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">20089781</pub-id></mixed-citation></ref><ref id="pone.0011165-International1"><label>39</label><mixed-citation publication-type="journal"><collab>International Zinc Nutrition Consultative Group</collab><year>2004</year><article-title>Assessment of the Risk of Zinc Deficiency in Populations and Options for its Control.</article-title><source>Food Nutr Bull</source><volume>25</volume><fpage>94S</fpage><lpage>203S</lpage></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002B37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:2887362
|texte= Micronutrient Fortification to Improve Growth and Health of Maternally HIV-Unexposed and Exposed Zambian Infants: A Randomised Controlled Trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:20567511" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |